CD4 and melanoma: In order to confirm the immunoprevalence of each MELOE-1 region in melanoma patients, and to characterize the Th type of CD4 specific T cells, we stimulated 10 melanoma patients PBMC with the MELOE-1 whole protein, and tested the reactivity of stimulated lymphocytes towards the regions: 2–21, 11–30, and 22–46.